Valuation: VISD GP

Market Cap 48.44M 55.74M 45.23M 41.52M 78.29M 5.31B 79.65M 533M 209M 2.65B 209M 205M 8.74B P/E 2024
44.3x
P/E 2025 31.3x
Enterprise Value 48.57M 55.88M 45.34M 41.63M 78.49M 5.33B 79.86M 535M 209M 2.66B 210M 205M 8.76B EV / Sales 2024
3.3x
EV / Sales 2025 3.04x
Free-Float
99.83%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 36 22/01/2024
Investor Relations Contact - -
Chief Executive Officer - 01/04/2022
Director TitleAgeSince
Chairman - -
Director/Board Member - 01/04/2022
Director/Board Member 51 14/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
+0.90%-1.59%+68.67%+41.78% 134B
+1.00%+4.36%+13.91%+50.18% 88.03B
-0.57%+0.72%+7.54%+59.07% 29.01B
-0.45%+0.05%+35.76%+69.69% 25.6B
+1.47%+1.64%-7.45%-15.68% 22.18B
-1.88%+2.72%+58.13%+236.23% 20.13B
-2.67%-1.11%+68.75%+130.09% 15B
-1.67%+1.37%+5.12%-1.39% 14.73B
-6.72%-1.87%-1.96%-9.74% 13.68B
Average -1.19%+1.30%+27.61%+62.25% 40.31B
Weighted average by Cap. +0.04%+0.96%+37.70%+54.40%

Financials

2024 2025
Net sales 17.26M 19.86M 16.11M 14.79M 27.89M 1.89B 28.38M 190M 74.42M 944M 74.6M 72.94M 3.11B 22.17M 25.5M 20.69M 19M 35.82M 2.43B 36.45M 244M 95.57M 1.21B 95.8M 93.68M 4B
Net income 1.4M 1.62M 1.31M 1.2M 2.27M 154M 2.31M 15.47M 6.06M 76.84M 6.07M 5.94M 253M 2.28M 2.62M 2.13M 1.95M 3.69M 250M 3.75M 25.11M 9.83M 125M 9.86M 9.64M 411M
Net Debt 2.58M 2.96M 2.4M 2.21M 4.16M 282M 4.23M 28.35M 11.1M 141M 11.13M 10.88M 465M 125K 144K 117K 107K 202K 13.71M 206K 1.38M 539K 6.84M 540K 528K 22.55M
Logo VISD GP
Founded in 2007, Klea Holding is a group focused on acquiring, developing and digitizing companies in various sectors to maximize their growth and value. Through its "scaling industries of the future" identity, Klea Holding draws on its successful experience in developing Smart Salem, the first network of digitalized medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the United Arab Emirates, its joint venture Smart Health, dedicated to the roll-out of digital medical testing centres in Saudi Arabia; and Klea Pharmaceuticals, a subsidiary dedicated to the commercialisation of a portfolio of licensed medicines in the Middle East and Africa.
Employees
-